Literature DB >> 22436384

[Blood pressure control in hypertensive Spanish population attended in primary care setting. The PRESCAP 2010 study].

José L Llisterri Caro1, Gustavo C Rodríguez Roca, Francisco J Alonso Moreno, Miguel A Prieto Díaz, José R Banegas Banegas, Diego Gonzalez-Segura Alsina, Salvador Lou Arnal, Juan A Divisón Garrote, Pere Beato Fernández, Vivencio Barrios Alonso.   

Abstract

BACKGROUND AND
OBJECTIVE: This study was aimed at determining the degree of blood pressure (BP) control in hypertensive patients attended in primary care (PC) settings. PATIENTS AND
METHOD: Cross-sectional, multicenter study. Hypertensive patients ≥18 years under antihypertensive treatment attended in Spanish PC settings were included. BP control was regarded as optimum when BP values were <140/90mmHg in general population and <130/80mmHg in patients with diabetes, chronic renal disease or cardiovascular disease. BP control was also calculated for all patients when it was <140/90mmHg.
RESULTS: A total of 12,961 hypertensive patients (52.0% women) with a mean age of 66.3 (±11.4) years were included. A percentage of 46.3 (95% CI: 45.4-47.1) presented good systolic BP and diastolic BP control; 61.1% (IC 95%: 60.2-61.9) of patients presented good BP control<140/90. A percentage of 63.6% was treated with combination therapy (44.1% with 2 drugs, 19.5% with 3 or more). BP control was significantly higher in evening measurements (50.4%) than in morning measurements (45.1%), and in patients who had taken the treatment before the visit (47.9%) compared with those who had not (30.5%). Factors such as not taking the medication before the visit, heavy alcohol consumption and dyslipemia were the risk factors mostly associated with a poor BP control (P<.001).
CONCLUSIONS: Five out of 10 hypertensive patients treated in PC settings have an optimal BP control. The degree of control of arterial hypertension has improved with respect to the PRESCAP 2006 study.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22436384     DOI: 10.1016/j.medcli.2011.10.023

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  5 in total

1.  [Objective KONTROL study: therapeutic inertia in hypertensive patients attended in primary care of Spain].

Authors:  Carlos Sanchis Doménech; José Luis Llisterri Caro; Vicente Palomo Sanz; Francisco Javier Alonso Moreno; Isidro López Rodríguez; Armando Nevado Loro; Miguel Ángel Zamorano; Natividad Gil García; M Dolores Aguilar Conesa; Pablo Lázaro Y de Mercado
Journal:  Aten Primaria       Date:  2011-03-17       Impact factor: 1.137

2.  Descriptive study of the patients treated at the clinic "integrated dentistry for patients with special needs" at Complutense University of Madrid (2003-2012).

Authors:  Marta Monteserín-Matesanz; Germán C Esparza-Gómez; Begoña García-Chías; Carmen Gasco-García; Rocío Cerero-Lapiedra
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-03-01

3.  [Effects of a recreational general physical activity program with short term and moderate intensity of blood pressure and other cardiovascular risk factors in hypertensive patients over 50 years old].

Authors:  Ana Torija Archilla; Javier Pérez González; Álvaro Sarmiento Ramírez; Enrique Fernández Sánchez; Josué Rubén González Ruiz; Rafael Guisado Barrilao
Journal:  Aten Primaria       Date:  2017-02-07       Impact factor: 1.137

4.  Protocol for assessing the hypotensive effect of evening administration of acetylsalicylic acid: study protocol for a randomized, cross-over controlled trial.

Authors:  Ma Victoria Ruíz-Arzalluz; Ma Cruz Gómez Fernández; Natalia Burgos-Alonso; Ernest Vinyoles; Ricardo San Vicente Blanco; Gonzalo Grandes
Journal:  Trials       Date:  2013-07-27       Impact factor: 2.279

5. 

Authors:  Carlos Brotons Cuixart; José Juan Alemán Sánchez; José Ramón Banegas Banegas; Carlos Fondón León; José María Lobos-Bejarano; Enrique Martín Rioboó; Jorge Navarro Pérez; Domingo Orozco-Beltrán; Fernando Villar Álvarez
Journal:  Aten Primaria       Date:  2018-05       Impact factor: 1.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.